Literature DB >> 26051952

Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease.

Lisa J Martin1, James P Franciosi2, Margaret H Collins3, J Pablo Abonia4, James J Lee5, Kevin A Hommel6, James W Varni7, J Tommie Grotjan8, Michael Eby8, Hua He9, Keith Marsolo10, Philip E Putnam11, Jose M Garza12, Ajay Kaul11, Ting Wen4, Marc E Rothenberg13.   

Abstract

BACKGROUND: The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS v2.0) measures patient-relevant outcomes. However, whether patient-identified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting, and pain) align with clinical symptomology and histopathologic and molecular features of eosinophilic esophagitis (EoE) is unclear.
OBJECTIVE: The purpose of this study was to determine whether clinical features of EoE, measured through PEESS v2.0, associate with histopathologic and molecular features of EoE. This represents a novel approach for analysis of allergic diseases, given the availability of allergic tissue biopsy specimens.
METHODS: We systematically recruited treated and untreated pediatric patients with EoE (aged 2-18 years) and examined parent proxy-reported symptoms using the PEESS v2.0. Clinical symptomology was collected by questionnaire. Esophageal biopsy samples were quantified for levels of eosinophils, eosinophil peroxidase (EPX) immunohistochemical staining, and mast cells. Molecular features were assessed by using the EoE Diagnostic Panel (94 EoE-related gene transcripts). Associations between domain scores and clinical symptoms and biological features were analyzed with Wilcoxon rank sum and Spearman correlation.
RESULTS: The PEESS v2.0 domains correlated to specific parent-reported symptoms: dysphagia (P = .0012), GERD (P = .0001), and nausea/vomiting (P < .0001). Pain correlated with multiple symptoms (P < .0005). Dysphagia correlated most strongly with overall histopathology, particularly in the proximal esophagus (P ≤ .0049). Markers of esophageal activity (EPX) were significantly associated with dysphagia (strongest r = 0.37, P = .02). Eosinophil levels were more associated with pain (r = 0.27, P = .06) than dysphagia (r = 0.24, P = .13). The dysphagia domain correlated most with esophageal gene transcript levels, predominantly with mast cell-specific genes.
CONCLUSION: We have (1) established a validated, parent proxy-reported measure for pediatric EoE, the PEESS v2.0; (2) verified that the parent proxy effectively captures symptoms; (3) determined that the dysphagia domain most closely aligns with symptoms and tissue-based molecular biomarkers; (4) established that symptoms correlate with EPX staining; and (5) observed association between mast cells and dysphagia.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergy; mast cells; microarray; molecular genetics; patient-reported outcomes; pediatrics; quality of life; reflux; surveys

Mesh:

Substances:

Year:  2015        PMID: 26051952      PMCID: PMC4460579          DOI: 10.1016/j.jaci.2015.03.004

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  53 in total

1.  Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis.

Authors:  Amir F Kagalwalla; Timothy A Sentongo; Sally Ritz; Therese Hess; Suzanne P Nelson; Karan M Emerick; Hector Melin-Aldana; B U K Li
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-21       Impact factor: 11.382

2.  Eosinophilic esophagitis: a 10-year experience in 381 children.

Authors:  Chris A Liacouras; Jonathan M Spergel; Eduardo Ruchelli; Ritu Verma; Maria Mascarenhas; Edisio Semeao; Jonathan Flick; Janice Kelly; Terry Brown-Whitehorn; Petar Mamula; Jonathan E Markowitz
Journal:  Clin Gastroenterol Hepatol       Date:  2005-12       Impact factor: 11.382

3.  Dietary treatment modulates mast cell phenotype, density, and activity in adult eosinophilic oesophagitis.

Authors:  Á Arias; A J Lucendo; P Martínez-Fernández; A M González-Castro; M Fortea; J González-Cervera; J L Yagüe-Compadre; T Mota-Huertas; M Vicario
Journal:  Clin Exp Allergy       Date:  2016-01       Impact factor: 5.018

4.  Clinical presentation of patients with eosinophilic inflammation of the esophagus.

Authors:  Sachin Baxi; Sandeep K Gupta; Nancy Swigonski; Joseph F Fitzgerald
Journal:  Gastrointest Endosc       Date:  2006-07-26       Impact factor: 9.427

5.  Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis.

Authors:  Carine Blanchard; Ning Wang; Keith F Stringer; Anil Mishra; Patricia C Fulkerson; J Pablo Abonia; Sean C Jameson; Cassie Kirby; Michael R Konikoff; Margaret H Collins; Mitchell B Cohen; Rachel Akers; Simon P Hogan; Amal H Assa'ad; Philip E Putnam; Bruce J Aronow; Marc E Rothenberg
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

6.  Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse.

Authors:  Isabelle Spik; Céline Brénuchon; Véronique Angéli; Delphine Staumont; Sébastien Fleury; Monique Capron; François Trottein; David Dombrowicz
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

7.  IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids.

Authors:  Carine Blanchard; Melissa K Mingler; Maria Vicario; J Pablo Abonia; Yi Ying Wu; Thomas X Lu; Margaret H Collins; Philip E Putnam; Susanne I Wells; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2007-12       Impact factor: 10.793

8.  Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease.

Authors:  Baishali Bhattacharya; James Carlsten; Edmond Sabo; Sripathi Kethu; Patricia Meitner; Rosemarie Tavares; Shriram Jakate; Shamlal Mangray; Bassam Aswad; Murray B Resnick
Journal:  Hum Pathol       Date:  2007-09-27       Impact factor: 3.466

9.  Prostaglandin D2 receptor D-type prostanoid receptor 2 mediates eosinophil trafficking into the esophagus.

Authors:  S Zhang; X Wu; S Yu
Journal:  Dis Esophagus       Date:  2013-10-25       Impact factor: 3.429

10.  Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.

Authors:  Marc E Rothenberg; Ting Wen; Allison Greenberg; Oral Alpan; Benjamin Enav; Ikuo Hirano; Kari Nadeau; Sergio Kaiser; Thomas Peters; Antonio Perez; Ieuan Jones; Jonathan P Arm; Robert M Strieter; Ronald Sabo; Kulasiri A Gunawardena
Journal:  J Allergy Clin Immunol       Date:  2014-09-13       Impact factor: 10.793

View more
  50 in total

Review 1.  Management of proton pump inhibitor responsive-esophageal eosinophilia and eosinophilic esophagitis: controversies in treatment approaches.

Authors:  Bharati Kochar; Evan S Dellon
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-12       Impact factor: 3.869

2.  Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites.

Authors:  Seema S Aceves; Eileen King; Margaret H Collins; Guang-Yu Yang; Kelley E Capocelli; J Pablo Abonia; Dan Atkins; Peter A Bonis; Christina L Carpenter; Evan S Dellon; Michael D Eby; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; Kendra Kocher; Jeffrey P Krischer; John Leung; Jessi Lipscomb; Paul Menard-Katcher; Vincent A Mukkada; Zhaoxing Pan; Jonathan M Spergel; Qin Sun; Barry K Wershil; Marc E Rothenberg; Glenn T Furuta
Journal:  J Allergy Clin Immunol       Date:  2018-05-29       Impact factor: 10.793

3.  Gene expression-phenotype associations in adults with eosinophilic esophagitis.

Authors:  Evan S Dellon; Sara R Selitsky; Robert M Genta; Richard H Lash; Joel S Parker
Journal:  Dig Liver Dis       Date:  2018-03-27       Impact factor: 4.088

Review 4.  Eosinophilic esophagitis phenotypes: Ready for prime time?

Authors:  Dan Atkins; Glenn T Furuta; Chris A Liacouras; Jonathan M Spergel
Journal:  Pediatr Allergy Immunol       Date:  2017-05-04       Impact factor: 6.377

5.  Noninvasive Diagnosis of Eosinophilic Esophagitis: The Nuclear Medicine Option.

Authors:  Benjamin L Wright; Hirohito Kita
Journal:  Mayo Clin Proc       Date:  2020-03       Impact factor: 7.616

6.  An algorithm for the classification of mRNA patterns in eosinophilic esophagitis: Integration of machine learning.

Authors:  Benjamin F Sallis; Lena Erkert; Sherezade Moñino-Romero; Utkucan Acar; Rina Wu; Liza Konnikova; Willem S Lexmond; Matthew J Hamilton; W Augustine Dunn; Zsolt Szepfalusi; Jon A Vanderhoof; Scott B Snapper; Jerrold R Turner; Jeffrey D Goldsmith; Lisa A Spencer; Samuel Nurko; Edda Fiebiger
Journal:  J Allergy Clin Immunol       Date:  2017-12-19       Impact factor: 10.793

7.  Eosinophilic esophagitis (EoE) genetic susceptibility is mediated by synergistic interactions between EoE-specific and general atopic disease loci.

Authors:  Lisa J Martin; Hua He; Margaret H Collins; J Pablo Abonia; Joceyln M Biagini Myers; Michael Eby; Hanna Johansson; Leah C Kottyan; Gurjit K Khurana Hershey; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2017-11-10       Impact factor: 10.793

Review 8.  Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach.

Authors:  Mery Munoz-Persy; Alfredo J Lucendo
Journal:  Eur J Pediatr       Date:  2018-03-17       Impact factor: 3.183

9.  Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis.

Authors:  David W Morris; Emily M Stucke; Lisa J Martin; J Pablo Abonia; Vincent A Mukkada; Philip E Putnam; Marc E Rothenberg; Patricia C Fulkerson
Journal:  J Allergy Clin Immunol       Date:  2016-05-16       Impact factor: 10.793

Review 10.  Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?

Authors:  Emily Ko; Mirna Chehade
Journal:  Clin Rev Allergy Immunol       Date:  2018-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.